Abingworth
Venture capitalLondon · Pre-Seed–Late Stage · 31 people tracked
Investment thesis
Abingworth invests in biopharma companies developing important new treatments across diverse disease areas and modalities. The firm pursues a multi-stage approach, backing seed and early-stage companies exploring novel mechanisms of disease, development-stage firms advancing programs through clinical trials, and later-stage companies seeking creative financing for expensive clinical trials. By maintaining a broad portfolio across biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, and cell therapies, Abingworth gains unique insight into success factors across biotechnology and positions itself to support companies through their entire development trajectory to market.
Source: firm website, verified Jul 21, 2026.
Team · 31 people
from the firm's websiteWhat they invest in
from 1 of 1 portfolio companiesBiotech ×1Medical Devices ×1
Investments · 1 tracked
founders shown can be your intro pathAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
BiotechMedical Devices
Frequently asked questions
- What stage does Abingworth invest at?
- Abingworth invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Abingworth's typical check size?
- Abingworth typically writes checks of $15M – $30M.
- What sectors does Abingworth focus on?
- Abingworth focuses on Biotech, Healthtech, Medical Devices.
- Where is Abingworth located?
- Abingworth is headquartered in London, GB.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.
Novo Holdings is a holding and investment company managing the assets of the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm invests in life science companies across all development stages and manages a diversified portfolio including equities, bonds, real estate, infrastructure, and private equity.
Apple Tree Partners is a life sciences venture capital firm that creates and builds transformative biotechnology companies from early-stage science through public markets. The firm works with scientists at various stages, from pre-IP ideas to company spinouts, providing capital, strategic guidance, and operational resources.